Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

What the long COVID treatment research actually shows

Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

There is no approved treatment for long COVID. That sentence hides a lot of work: several of the leading theories have now been put to a proper randomized test, and the results are worth knowing, especially if you are being offered an expensive treatment based on one of them.

Here is what has been tested, what the results were, and what is still open.

Related pages: Long COVID · Chronic fatigue syndrome (ME/CFS)

The bottom line

What we know
  • No drug is approved to treat long COVID.
  • Metformin given early during a COVID infection lowered the chance of developing long COVID by about 41% in a randomized trial.
  • Pacing, meaning staying under the effort level that triggers a crash, is the mainstay of management.
  • Exercise programs that push through post-exertional malaise can cause lasting harm.
What is still open
  • Whether antivirals help a subgroup, with longer courses or different patients.
  • Whether immune-targeting drugs will work.
  • Whether treating the serotonin or autonomic pathways will help.

The story, step by step

  1. 1. Antivirals (Geng, Singh and colleagues, 2024 (STOP-PASC))
  2. 2. Prevention (Bramante and colleagues, 2023 (COVID-OUT))
  3. 3. Blood treatments (Randomized trial of therapeutic plasma exchange; Fraser and colleagues 2026)
  4. 4. Pacing (Clinical consensus plus the muscle biopsy evidence)
  5. 5. What's in trials (Trial programs including the US RECOVER initiative)
  6. 6. Avoiding it (Vaccine cohort studies and trial evidence)
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 6

Paxlovid for long COVID: tested, and it didn't work

Geng, Singh and colleagues, 2024 (STOP-PASC)JAMA Internal Medicine, StanfordRandomized trial

What happens

155 people with long COVID symptoms lasting over 3 months were randomly given a 15-day course of nirmatrelvir-ritonavir (Paxlovid) or a placebo, double-blinded. This tested the viral-reservoir theory directly: if leftover virus is driving symptoms, an antiviral should help.

What the research shows

  • There was no significant difference at 10 weeks in the main outcome or in secondary outcomes including breathlessness, standing vital signs and thinking tests.
  • Both groups improved over time, which on its own is useful to know.
  • The 15-day course, three times the usual length, was safe.

Why it matters

The first real test of the leading theory came back negative. That doesn't disprove viral persistence, but it does mean nobody should be sold a long Paxlovid course as an established long COVID treatment.

What's still uncertain

  • Single center, mostly vaccinated participants, with symptoms already lasting about 3 months.
  • It doesn't rule out benefit in a subgroup, with a different dose, or earlier in the illness. The researchers said as much.
  • The trial was funded by Pfizer, the maker of the drug.

Read more

Next: Prevention

Part 2 of 6

Metformin during the infection: the one clear positive result

Bramante and colleagues, 2023 (COVID-OUT)The Lancet Infectious DiseasesRandomized trial

What happens

A randomized, quadruple-blind trial gave metformin, ivermectin, fluvoxamine or placebo to overweight adults aged 30 to 85 within 7 days of COVID symptoms starting, then followed them for 10 months.

What the research shows

  • Long COVID occurred in 6.3% of the metformin group and 10.4% of the placebo group, a 41% reduction.
  • Started within about 3 days of symptoms, the reduction was 63%.
  • Neither ivermectin nor fluvoxamine reduced long COVID.
  • Metformin is cheap, widely available and long established as a diabetes drug.

Why it matters

This is prevention, not treatment: it is about what happens during the acute infection, not once long COVID has set in. It is the strongest randomized evidence of anything reducing long COVID.

What's still uncertain

  • Participants were overweight or obese adults in a particular age range, so it may not generalize.
  • About half were unvaccinated, and the variants circulating then were not today's.
  • The outcome was a reported long COVID diagnosis, not a standardized assessment.
  • This is not a reason to take metformin now. It is a prescription medicine and the finding applies to starting it in the first days of an infection.

Read more

Next: Blood treatments

Part 3 of 6

Plasma exchange and blood thinners: no support so far

Randomized trial of therapeutic plasma exchange; Fraser and colleagues 2026Randomized trial

What happens

Because of the microclot theory, several treatments aimed at the blood have been promoted, including plasma exchange (filtering the blood), anticoagulants, and enzyme supplements. A phase 2 double-blind randomized trial tested plasma exchange.

What the research shows

  • Plasma exchange was safe, but there was no difference between groups in any measure of effectiveness.
  • A 2026 Oxford study of never-hospitalized long COVID patients found no evidence of the clotting abnormalities these treatments target.
  • Those authors concluded anticoagulant therapy is not justified outside trials, in the absence of a separate recognized reason for it.

Why it matters

Clinics offering blood washing, anticoagulants or 'microclot protocols' for long COVID are working ahead of the evidence, and these treatments carry real risks, including bleeding.

What's still uncertain

  • Absence of benefit in these trials doesn't prove no subgroup is helped.
  • The research on clotting after severe, hospitalized COVID is a separate question.

Read more

Next: Pacing

Part 4 of 6

Pacing, and why push-through exercise is the wrong model

Clinical consensus plus the muscle biopsy evidenceLarge observational study

What happens

Pacing means keeping activity below the level that triggers a crash, rather than steadily increasing it.

What the research shows

  • Muscle biopsies taken a day after maximal exercise showed severe muscle damage, cell death and immune infiltration in long COVID patients, worse than before the test.
  • Researchers in that study concluded some classic forms of rehabilitation and physiotherapy are counterproductive for these patients.
  • Specialists in this area state plainly that post-exertional malaise is not deconditioning and cannot be fixed by going to the gym.

Why it matters

Pacing isn't a cure and it isn't giving up. It is working within a limit that is biologically real, so you aren't repeatedly causing damage.

What's still uncertain

  • No randomized trial has proven pacing changes the long-term course. It is based on mechanism plus the harm seen from the alternative.
  • People without post-exertional malaise may be able to build activity gradually. That distinction matters, which is why any rehab program should be asked about it.

Read more

Next: What's in trials

Part 5 of 6

What is being tested now

Trial programs including the US RECOVER initiativeRandomized trial

What happens

Trials are now organized around the proposed mechanisms rather than treating long COVID as one thing.

What the research shows

  • Antiviral approaches with longer courses or different drugs, aimed at the viral reservoir.
  • Immune-targeting drugs, including existing treatments borrowed from autoimmune disease.
  • Treatments for specific features, such as orthostatic intolerance and sleep, which can help function even without curing the illness.
  • Approaches aimed at the vagus nerve and serotonin pathway, following the 2023 Cell findings.

Why it matters

The honest position is that the field is early, and that trials are the way out of it. Participating in one is a reasonable thing to ask your doctor about.

What's still uncertain

  • Early results from small or uncontrolled studies have repeatedly failed to hold up in long COVID. Treat anything not yet randomized as unproven.
  • No treatment currently has regulatory approval for long COVID anywhere.

Read more

Next: Avoiding it

Part 6 of 6

Lowering the odds in the first place

Vaccine cohort studies and trial evidenceLarge observational study

What happens

Researchers compared long COVID rates by vaccination status and by number of infections.

What the research shows

  • Studies by one large group found vaccination reduced long COVID risk by roughly 40% to 50%.
  • Other analyses have found a smaller or unclear effect, so the size of the benefit is genuinely debated.
  • Each new infection carries its own chance of long COVID, so avoiding repeat infections matters.
  • Metformin started early in infection reduced risk by 41% in the trial above.

Why it matters

Not catching COVID again, and being vaccinated when you do, are the two levers most people actually have.

What's still uncertain

  • Vaccination clearly reduces severe illness. Its effect specifically on long COVID is less certain, and estimates vary between studies.
  • None of this helps someone who already has long COVID.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.